Media ReleasesCyclopharm

View All Cyclopharm News


Cyclopharm - USFDA Approval Progress for Technegas and Business Update


Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on its progress towards gaining United States Food and Drug Administration (“USFDA”) approval to begin sales of Technegas™  into the US, preliminary (unaudited) revenue performance for FY20 and other operational matters.

For more information, download the attached PDF.

Download this document